UNION therapeutics announces presentation of Phase 2b results with oral orismilast at the AAD Annual Meeting 2023
· Late-breaking presentation of results from the Phase 2b IASOS study of oral orismilast in psoriasis to be presented at the American Academy of Dermatology (AAD) Annual Meeting 2023 · Positive topline data from the IASOS study reported early January 2023, supporting the target product profile of oral orismilast as a best-in-class PDE4 inhibitor · Orismilast is a high-potency PDE4 inhibitor with broad anti-inflammatory properties in development for oral treatment of atopic dermatitis (AD), psoriasis and hidradenitis suppurativa (HS) Hellerup, Denmark, March 13, 2023 – UNION